{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:14:59Z","timestamp":1763018099035,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,10,22]]},"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>This is a case report of a 48-year-old woman who presented with heavy per vaginal bleeding to the emergency department after being commenced on direct oral anticoagulants (DOACs) for venous thromboembolism. She had significant bleeding which initially required resuscitation and stabilisation. Her symptoms were ultimately managed by changing her anticoagulation agent to therapeutic low molecular weight heparin with Clexane<jats:sup>\u00a9<\/jats:sup> the agent of choice. This case study highlights the complexity of managing these patients as well as highlighting the need for ongoing research into DOACs in this area.<\/jats:p>","DOI":"10.1136\/bcr-2018-225727","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T05:06:12Z","timestamp":1574226372000},"page":"e225727","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["<i>\u200b<\/i>Challenge in managing abnormal uterine bleeding in a patient on novel oral anticoagulant therapy"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-4013","authenticated-orcid":false,"given":"Sophia","family":"Bilal","sequence":"first","affiliation":[{"name":"O&G, Gosford District Hospital, Gosford, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"2025082711232446000_12.11.e225727.1","unstructured":"Heavy menstrual bleeding: assessment and management . Guidance and guidelines, NICE [Internet]. Nice.org.uk, 2018. Available: https:\/\/www.nice.org.uk\/guidance\/cg44\/chapter\/recommendations [Accessed 2018 Apr 23]."},{"key":"2025082711232446000_12.11.e225727.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.07.030"},{"key":"2025082711232446000_12.11.e225727.3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bjh.13583","article-title":"Heavy menstrual bleeding on rivaroxaban","volume":"173","author":"Ferreira","year":"2016","journal-title":"Br J Haematol"},{"key":"2025082711232446000_12.11.e225727.4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.vph.2016.11.003","article-title":"Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism","volume":"87","author":"Bryk","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"2025082711232446000_12.11.e225727.5","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(16)30111-9","article-title":"Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series","volume":"3","author":"Beyer-Westendorf","year":"2016","journal-title":"Lancet Haematol"},{"key":"2025082711232446000_12.11.e225727.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.05.001","article-title":"Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism","volume":"93-95","author":"Godin","year":"2017","journal-title":"Vascul Pharmacol"},{"key":"2025082711232446000_12.11.e225727.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665927"},{"key":"2025082711232446000_12.11.e225727.8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2018.03.004","article-title":"An opinion on the benefits of concomitant oral contraceptive therapy in premenopausal women treated with oral anticoagulants","volume":"165","author":"Godin","year":"2018","journal-title":"Thromb Res"},{"key":"2025082711232446000_12.11.e225727.9","doi-asserted-by":"crossref","unstructured":"Ferreira M , Klok F , Feuring M , et al . Dabigatran is associated with a significantly lower risk of abnormal uterine bleeding than warfarin in female patients of childbearing age with venous thromboembolism. Blood;128:140\u20131.","DOI":"10.1182\/blood.V128.22.140.140"},{"key":"2025082711232446000_12.11.e225727.10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1160\/TH16-11-0874","article-title":"Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin","volume":"117","author":"Brekelmans","year":"2017","journal-title":"Thromb Haemost"},{"key":"2025082711232446000_12.11.e225727.11","doi-asserted-by":"crossref","unstructured":"Bryant-Smith AC , Lethaby A , Farquhar C , et al . Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2018;313. Art. No: CD000249.doi:10.1002\/14651858.CD000249.pub2","DOI":"10.1002\/14651858.CD000249.pub2"},{"key":"2025082711232446000_12.11.e225727.12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3629.3629","article-title":"Tranexamic acid is a weak provoking factor for thromboembolic events: a systematic review of the literature","volume":"122","author":"Chan","year":"2013","journal-title":"Blood"},{"key":"2025082711232446000_12.11.e225727.13","doi-asserted-by":"crossref","unstructured":"Lethaby A , Hussain M , Rishworth JR , et al . Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2015;108. Art. No: CD002126.doi:10.1002\/14651858.CD002126.pub3","DOI":"10.1002\/14651858.CD002126.pub3"},{"key":"2025082711232446000_12.11.e225727.14","doi-asserted-by":"crossref","unstructured":"Boonyawat K , O\u2019Brien S , Bates S . How we treat heavy menstrual bleeding associated with anticoagulants.. Blood 2017:07\u2013797423.","DOI":"10.1182\/blood-2017-07-797423"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-225727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:23:35Z","timestamp":1756319015000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-225727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,19]]},"published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1136\/bcr-2018-225727"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-225727","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}